Finance

A couple of popular institutional trades are driving much of the purchasing activity.

NEAR Protocol is soaring in value this year, but how long can it keep up this performance?

BBH concentrates on 25 large-cap biotech leaders, while XPH diversifies across 62 pharmaceutical holdings. Both charge 0.35% annually, but their five-year returns diverged significantly.

Viking’s weight loss pill program has a couple of issues, including the fierce competitors who have a big head start.

The LEO satellite developer still has plenty of upside potential.

Pay close attention so you don’t miss out on any key details.

It plays a critical role in AI development.

Zcash’s trajectory suggests that even bigger gains are on the way.

An Anthropic IPO will boost several companies.

What does it mean for shareholders when a chipmaker can’t make processors fast enough?

Hybrid-electric demonstrator nears completion as cash runway extends to 24 months.

Revenue surged 16% on strong travel demand, but fuel costs climbed $500M above guidance.

Federal Reserve Chairman Kevin Warsh has changed the dynamics of the Fed’s communications, but he hasn’t changed the Fed’s mandate.

ConocoPhillips is evaluating an unsolicited offer for some of its assets, and the numbers sound huge.

A pundit at a global bank initiated coverage of the company.

The biotech could play a significant role in a national effort to combat cancer.

A rival chipmaker agreed last month to pay $8.2 billion in shares to push further into this area of AI.

Are you prepared for this benefit change to hit your check?

It was one of four companies identified by an analyst team as historical outperformers following major storms.

An analyst raised his price target on the cybersecurity company by 24%.